The Novavax Covid-19 Vaccine Candidate May Outshine Major Companies

Image: Recombinant Protein Nanoparticles – Novavax. Article by Hannah C.

In 2019, Novavax nearly closed down after bad management and failed vaccine trials. Today, they are one of the leading companies recognized in developing a coronavirus vaccine. In September, their coronavirus vaccine candidate, NVX-CoV2373, began late-stage clinical trials in the United Kingdom. The United States and Mexico will also […]

Click here to view original web page at www.sciencetimes.com